Advance the diagnosis, treatment, control, and community engagement of tropical diseases, with a main focus on febrile syndromes such as malaria, trypanosomiasis, and bacterial infections.
2.Improve treatment options by assessing new compounds with novel mechanisms against AMR. (i) In vivo: efficacy clinical trials for malaria (KAF156-Lumefantrine in Mali, triple ACT in Angola with INIS/Oxford). (ii) In vitro: advanced cell culture systems simulating human pharmacokinetics to support pre-clinical drug development and define physiologically aligned resistance models. Additionally, drug-drug interaction studies will be conducted to identify optimal combinations. Mechanistic studies will address resistance to lumefantrine and amodiaquine (with VBD, using animal/in silico models);
3.Strengthen malaria control through population-based studies in São Tomé and Príncipe (with Guinea-Bissau (with Bloodless Bandim Health Project), and the Brazilian Amazon (with INSP), USP/ICB )Research focuses on host–parasite factors sustaining transmission, especially submicroscopic infections, using ultra-sensitive qPCR (with Fiocruz Minas). Additional work includes HLA polymorphisms and haemoglobinopathies, applied to migrant surveillance in Portugal (with PPS cohort). Local elimination efforts include tracking drug resistance phenotypes and genetic markers using next-generation sequencing.
4.Travel medicine: (i) new research on gut microbiome changes in long-term travelers to tropical regions and links to chronic conditions (e.g., diabetes, obesity), exploring causal timelines, resilience, and microbiome based interventions; (ii) studies on imported infections in immune-naïve travelers as sentinels for emerging resistant pathogens (“canary in the mine” effect), reinforcing collaboration with national hospitals toward a CTM/GHTM-centered network; (iii) development of a national travel medicine network and risk assessment model, integrating with the GeoSentinel platform;
5.Mother & child health – addressing bacterial vaginosis via studying efflux in innate/acquired drug resistance of the vaginal microbiome, and assessing vaginal microbiota transplant efficacy vs pharmacological treatments for microbiome restoration;
CTM will continue training health professionals and supporting local expertise in diagnostics and tropical disease management.Two flagship programs—Curso de Formação em Investigação Clínica (FCG) and the 5 month Advanced Course on Clinical Tropical Medicine—train clinicians from the PALOP, Latin America, and Portugal in the management of tropical diseases.
It will continue participating in key networks: WHO (Chagas, HAT), DNDi, PLICIB, EDCTP, WWARN and TropNet.
Activities span multicentric drug trials, WHO initiatives for Chagas control, maternal health studies, malaria fieldwork, and translational research training.
Recent Highlights
Plenary Meeting brings the GHTM community together to shape its scientific strategy
GHTM researchers and students discuss the 2025–2029 scientific strategy, research performance and key scientific indicators from 2020 to 2025.
Read More
GHTM Plenary Meeting | 30 SEPTEMBER 2026
Join GHTM members to discuss the Strategic Plan and review research indicators from 2020–2025, shaping GHTM’s future priorities. In-person and online participation available.
Read More
EDCTP Forum 2027: Abstract Submissions Open Until 2 September
Submit your research and join global health leaders in Madrid in 2027 to share innovations, insights and impact in health research.
Read More
GHTM | IHMT NOVA Strengthens the Link Between Diagnostics and Research Through Advanced Clinical Laboratory Services
Discover how GHTM | IHMT NOVA advances infectious disease diagnostics through cutting-edge research, innovation and specialised laboratory expertise.
Read More
The TEAM
